Red Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease
Open Access
- 24 September 2019
- journal article
- research article
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 44 (5) , 1158-1165
Abstract
Background: Although reduced red blood cell (RBC) lifespan has been reported to be a contributory factor to anemia in patients with end-stage chronic kidney disease (CKD), there are limited data regarding RBC lifespan in early-stage CKD. Serum erythropoietin (EPO) is considered a primary causative factor of renal anemia. The aims of this study were to compare the RBC lifespan, serum EPO levels, and other renal anemia indicators across CKD-stage groups of patients and to analyze the impacts of etiological factors on renal anemia. Methods: A cohort of 74 non-smoking patients with CKD were enrolled, including 15 in stage 1, 18 in stage 2, 15 in stage 3, 15 in stage 4, and 11 in stage 5. RBC lifespan was determined by CO breath tests. Potential correlations of hemoglobin (Hb) concentration with RBC lifespan, reticulocyte count (Ret), and levels of EPO, ferritin, folic acid, and vitamin B12 were analyzed. Results: CKD progression was associated with decreases in (Hb) and RBC lifespan. RBC lifespan durations in CKD stages 1–5 were 122 ± 50, 112 ± 26, 90 ± 32, 88 ± 28, and 60 ± 24 days, respectively. RBC lifespan means for the stage 3, 4 and 5 groups were significantly shorter than those for the stage 1 and 2 groups. Serum EPO did not differ significantly between the CKD stage groups. (Hb) correlated directly with RBC lifespan (r = 0.372, p = 0.002) and Ret (r = 0.308, p = 0.011), but did not correlate with serum EPO, ferritin, folic acid, or vitamin B12 levels. Conclusions: Reduced RBC lifespan in early-stage CKD, demonstrated in this study, suggests that increased RBC destruction may play a more important etiological role in renal anemia than other indicators in patients with CKD.Keywords
This publication has 21 references indexed in Scilit:
- Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfateBMC Nephrology, 2013
- Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancerBritish Journal of Cancer, 2012
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Executive SummaryAmerican Journal of Kidney Diseases, 2006
- Red blood cell survival in chronic renal failureAmerican Journal of Kidney Diseases, 2004
- Role of uremic toxins in exacerbating anemia in renal failureKidney International, 2001
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998
- A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal diseaseAmerican Journal of Kidney Diseases, 1997
- The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietinKidney International, 1989